Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Decision on third dose of COVID-19 vaccine for all adults will be based on scientific need:…
Responding to a question at a weekly press conference, Dr V K Paul, Member (health), NITI Aayog, said all decisions on precaution…
DTAB recommends granting licence to manufacture, stock new drugs, jabs under clinical trial
Various industry experts and subject experts are of opinion that if the government approves recommendation of DTAB and DCGI, it…
India’s first homegrown mRNA COVID-19 vaccine currently under final clinical trial stages:…
The vaccine is being developed by Pune-based Gennova Biopharmaceuticals, informed Dr VK Paul, Member (health), NITI Aayog
IIT Jodhpur researchers identify COVID-19 RNA variations and their implications
The scientists have also studied the fixation of these intra-host variations into extra-host variations and mutations that lead to…
Vitamin Angels India and OmniActive Health Technologies partner to combat malnutrition in…
The partnership will ensure Vitamin A supplementation for 50,000 children under the age of five across six districts of…
Alembic Pharma reports net profit of Rs 176 crores in Q3FY22
The net profit of the company stands at Rs 176 crores for this quarter with net sales at Rs 1,272 crores
Lincoln Pharma reports 30.50 per cent rise in standalone net profit at Rs 17.60 crores in Q3 FY22
The company reported an EBITDA of Rs 26.09 crores in Q3FY22, a rise of 25.90 per cent as compared to Rs 20.72 crores in the…
New antiviral drug combo highly effective against coronavirus: Study
The research, published recently in the journal Nature, suggests that these drugs are more potent when used in combination than…
OPPI-QCI announce Quality Award for Excellent Facility of the year, 2021
The Award is instituted by OPPI in collaboration with QCI to recognise pharmaceutical facilities excelling in quality…
Siranomics begins phase-I trial of siRNA drug candidate STP707 to treat tumours
The phase-I clinical trial, a multi-centre, open-label, dose-escalation and dose-expansion study, will evaluate the safety,…